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Abstract
PURPOSE—Pathogenic variants in GJB2 are the most common cause of autosomal recessive 
sensorineural hearing loss. The classification of c.101T>C/p.Met34Thr and c.109G>A/p.Val37Ile 
in GJB2 are controversial. Therefore, an expert consensus is required for the interpretation of these 
two variants.
METHODS—The ClinGen Hearing Loss Expert Panel collected published data and shared 
unpublished information from contributing laboratories and clinics regarding the two variants. 
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Functional, computational, allelic, and segregation data were also obtained. Case-control statistical 
analyses were performed.
RESULTS—The panel reviewed the synthesized information, and classified the p.Met34Thr and 
p.Val37Ile variants utilizing professional variant interpretation guidelines and professional 
judgment. We found that p.Met34Thr and p.Val37Ile are significantly overrepresented in hearing 
loss patients, compared to population controls. Individuals homozygous or compound 
heterozygous for p.Met34Thr or p.Val37Ile typically manifest mild to moderate hearing loss. 
Several other types of evidence also support pathogenic roles for these two variants.
CONCLUSION—Resolving controversies in variant classification requires coordinated effort 
among a panel of international multi-institutional experts to share data, standardize classification 
guidelines, review evidence, and reach a consensus. We concluded that p.Met34Thr and p.Val37Ile 
variants in GJB2 are pathogenic for autosomal recessive nonsyndromic hearing loss with variable 
expressivity and incomplete penetrance.
Keywords
ClinGen; hearing loss; incomplete penetrance; variant classification; variant interpretation
INTRODUCTION
Variants with incomplete penetrance for Mendelian conditions pose significant challenges 
for clinical interpretation because they are relatively common in the population and present 
in healthy individuals1. No such variants have been rigorously reviewed and classified 
according to the American College of Medical Genetics and Genomics and the Association 
for Molecular Pathology (ACMG/AMP) guidelines2. To demonstrate the best practice to 
interpret such variants, the ClinGen Hearing Loss Expert Panel (HL-EP) applied hearing-
loss-gene-specific ACMG/AMP guidelines3 to interpret two controversial variants in GJB2.
GJB2 encodes connexin 26, a member of the gap junction protein family. Gap junctions are 
intercellular channels allowing the coupling of adjacent cells to share molecules, ions, and 
electrical signals. Each gap junction channel is composed of two connected hemichannels 
called connexons, one on either membrane of neighboring cells. Each connexon is a 
hexamer of the same or different connexin units. Biallelic pathogenic variants in GJB2 
(NM_004004.5) are the most frequently identified cause of autosomal recessive 
sensorineural hearing loss4,5. Hundreds of GJB2 variants have been reported in patients with 
hearing loss. Premature termination codons (PTC), such as c.35delG, c.167delT, and 
c.235delC common in European, Ashkenazi Jewish, and Asian populations respectively, are 
established pathogenic variants. However, classifications of two notable missense variants 
c.101T>C/p.Met34Thr and c.109G>A/p.Val37Ile have been controversial. P.Met34Thr was 
first reported as being associated with dominant hearing loss4, but its pathogenicity for 
dominant hearing loss was later challenged because of subsequent identification of its 
occurrence in individuals with normal hearing5,6, and an autosomal recessive mode of 
inheritance was suggested7–9. P.Val37Ile was first identified as a polymorphism in a 
heterozygous control10, and later found to be homozygous or in trans with known 
pathogenic GJB2 variants in affected individuals7,11. Both variants were found relatively 
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frequently in the general population. Some homozygotes for these variants appeared to have 
normal hearing12,13. Reduced penetrance was proposed to explain the inconsistency14. We 
surveyed clinical laboratories in the United States and Canada regarding the classification of 
these variants and found significant variability across different laboratories (Supplementary 
Information). Therefore, we considered it a priority to resolve the controversy and reach a 
consensus.
Herein, we report the ClinGen and ClinVar effort to resolve controversies regarding 
p.Met34Thr and p.Val37Ile classification assertions and demonstrate the best practice to 
interpret variants with incomplete penetrance.
MATERIALS AND METHODS
ClinGen Hearing Loss Expert Panel
The ClinGen HL-EP includes otolaryngologists caring for patients with hereditary hearing 
loss, medical geneticists, clinical laboratory diagnosticians, molecular pathologists, genetic 
counselors, and investigators specialized in auditory research3. This group was convened to 
develop specifications of the ACMG/AMP guidelines for interpreting sequence variants in 
genes associated to hearing loss3.
Data sources
Fifteen genetic testing laboratories and clinics contributed data to this study (Table 1). 
Individuals tested for p.Met34Thr or p.Val37Ile were designated as cases if hearing loss was 
the indication or as population controls if carrier screening was the indication. Counsyl data 
were solely based on carrier screening, thus representing the general population. We also 
considered information from the Genome Aggregation Database (gnomAD; http://
gnomad.broadinstitute.org/) as population controls. Testing methods included specific 
variant testing, GJB2 sequencing, large multigene panels, and exome sequencing. 
Individuals from sites with unspecified total numbers tested and relatives of probands were 
excluded from statistical analyses. Data collected included total number of individuals tested 
for p.Met34Thr or p.Val37Ile in GJB2, ethnicities, allele states, and phenotypic information 
(age at onset of hearing loss, age at testing, type of hearing loss, severity, laterality, 
frequency range affected, family history, and other clinical features). The study was 
approved by respective Institutional Review Boards, Helsinki Committees, or equivalent 
ethics committees of participating institutions involving research on human subjects.
Variant interpretation
Data were analyzed and interpreted according to ACMG/AMP guidelines2 and hearing-loss-
gene-specific criteria by the ClinGen HL-EP3. Original evidence codes included a first letter 
P (“pathogenic”) or B (“benign”), followed by VS (“very strong”), S (“strong”), M 
(“moderate”), P (“supporting”), or A ( “standard alone”) to indicate the strength level and a 
category number2. Modified codes included a suffix of an underscore and the adjusted 
strength level3.
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Statistical analysis
For 2×2 contingency tables, odds ratios (OR), 95% confidence intervals (CI), Z statistics, 
and p values were calculated using MEDCALC (https://www.medcalc.org/calc/
odds_ratio.php). Four types of case-population comparisons were performed: (1) 
homozygotes in overall populations, (2) homozygotes in ethnicity-stratified populations, (3) 
alleles in ethnicity-stratified populations, and (4) homozygotes and compound heterozygotes 
in ethnicity-stratified populations. GnomAD data were included except for analyses 
involving compound heterozygotes, where only Counsyl data were used as population 
controls, because individual data were unavailable in gnomAD. Compound heterozygosity 
was presumed in individuals with two variants in GJB2 never reported to have occurred in 
cis.
For comparisons of the severity among different genotype groups, an ordinal logistic 
regression model was used. No covariates such as age and sex were included, because the 
information was not available for all individuals. The proportions of the sample sizes of the 
genotype groups were used as weights for the analysis. Type 1 test was used to test the 
overall significant difference among all groups and ad-hoc analysis was performed to 
compare the estimated odds ratio between each pair of specific gene types. The statistical 
significance was defined as p value <0.05. The analysis was performed with SAS software 
(version 9.4).
RESULTS
Case-control Evidence
P.Met34Thr and p.Val37Ile have been reported in patients with hearing loss in various 
populations (Supplementary Information). To perform accurate case-control comparisons, 
the HL-EP decided not to rely on published cases in the literature due to concerns of the 
publication bias. Instead, we obtained data from 15 contributing sites (Table 1). The level of 
details provided by each site varied. Three sites (BCH, DY, and GDWC) reported only cases 
with biallelic GJB2 variants involving p.Met34Thr or p.Val37Ile. Eleven sites reported 
results from 17,635 probands with hearing loss tested for these two variants. Ethnicity 
information was available from eight sites on 7,962 European probands and 2,066 Asian 
probands. Five sites (Counsyl, CUHK, NTMC, TAU, and UNC) provided population 
screening data from 664,114 individuals, including 306,982 Europeans and 66,423 Asians 
(Tables 2 and 3).
We compared frequencies of individuals with these two variants between cases in our 
multicenter cohort and population controls. P.Met34Thr and p.Val37Ile homozygotes are 
significantly enriched in cases with ORs of 16 (95%CI 11–25, Z=13, p<0.0001) (Table 2) 
and 20 (95%CI 17–24, Z=31, p<0.0001) (Table 3) respectively.
Because the allele frequencies of p.Met34Thr and p.Val37Ile were observed highest in 
European and East Asian populations, respectively, we performed statistical analyses on 
stratified subpopulations by ethnicity to remove the confounding factor of different ethnic 
compositions between cases and controls. The significance still held when we performed 
ethnicity-specific analysis. P.Met34Thr homozygotes were significantly enriched in cases 
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over population controls in Europeans (OR=9.8, 95%CI=5.5–17, Z=7.8, p<0.0001) (Table 2) 
and p.Val37Ile homozygotes in Asians (OR=12, 95%CI=9.1–15, Z=19, p<0.0001) (Table 3), 
respectively. When we considered all biallelic cases involving p.Met34Thr or p.Val37Ile, 
including homozygotes and compound heterozygotes with another pathogenic variant in 
GJB2, the enrichments were more significant with ORs of 29 (95%CI 22–37, Z=25, 
p<0.0001) for p.Met34Thr in Europeans (Table 2) and of 19 (95%CI 15–24, Z=26, 
p<0.0001) for p.Val37Ile in Asians (Table 3) in cases with hearing loss in our multicenter 
cohort over those who underwent carrier screening at Counsyl. Therefore, both variants meet 
PS4 (prevalence in affecteds statistically increased over controls) according to ACMG/AMP 
guidelines2.
Although alleles were statistically enriched in cases in our multicenter cohort over the 
general population with ORs of 1.3 (95%CI 1.2–1.5, Z=4.2, p<0.0001) for p.Met34Thr in 
Europeans (Table 2) and of 1.7 (95%CI 1.5–1.9, Z=8.1, p<0.0001) for p.Val37Ile in Asians 
(Table 3), the ORs did not exceed 5 to satisfy PS4. We concluded that comparing genotype 
frequencies is more appropriate than comparing allele frequencies in case-control analyses 
to interpret variants associated with an autosomal recessive condition, because the 
unaffected heterozygous carriers contributed the majority of alleles.
Computational predictions
The REVEL scores were 0.702 and 0.657 for p.Met34Thr and p.Val37Ile, respectively. PP3 
(computational predictions support pathogenicity) could be applied to p.Met34Thr 
(REVEL>=0.7) but not to p.Val37Ile because its REVEL score did not reach the threshold 
(0.7) to support pathogenicity but exceeded the ceiling (0.15) to support a benign role as 
specified by the ClinGen HL-EP3.
Different amino acid changes at positions p.Met34 and p.Val37 have been reported in 
hearing loss patients (Supplementary Information). While they do not constitute sufficient 
evidence for PM5 (different change at the same residue as a known pathogenic variant), 
multiple variants of uncertain significance leaning towards pathogenicity affecting the same 
amino acid residues corroborate with each other.
Segregation Evidence
Literature review showed that both variants segregated with hearing loss in families. 
Furthermore, we reported at least 35 affected siblings with the same homozygous or 
compound heterozygous genotypes as probands, including 16 with p.Met34Thr and 21 with 
p.Val37Ile (Table S2). Therefore, both variants meet PP1_Strong (co-segregation in families, 
modified to strong)2,3.
P.Met34Thr and p.Val37Ile homozygotes were present in large population databases and 
identified by population carrier screening. However, clinical information was unavailable. 
Some individuals may be underdiagnosed. Furthermore, it has been reported that p.Val37Ile 
homozygotes lose hearing at ~1 dB/year15, implicating an age-dependent penetrance. The 
penetrance by young adulthood was estimated to be 17%16. Therefore, we did not consider 
hearing individuals with biallelic p.Met34Thr or p.Val37Ile as observations in controls or 
non-segregation.
Shen et al. Page 6
Genet Med. Author manuscript; available in PMC 2020 May 19.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Allelic Evidence
Both variants have been identified in affected homozygotes or compound heterozygotes. In 
our multicenter cohort, we observed 138 p.Met34Thr and 141 p.Val37Ile compound 
heterozygotes (Table S2). However, because of high population allele frequencies and large 
sample sizes, we applied PM3 (in trans with a pathogenic variant in an affected individual) 
without modifying to strong despite the large number of biallelic cases identified.
Functional Evidence
P.Met34Thr altered gap junction function in Xenopus oocytes17–19 and mammalian 
cells20–22. It had a similar subcellular localization pattern as wild-type connexin 26 in 
human sweat glands, in transfected HeLa cells, and in transfected COS-7 cells18,20,21. Paired 
Xenopus oocytes showed robust conductance when injected with in vitro transcribed human 
wild-type GJB2 mRNA, reduced conductance when co-injected with wild-type and variant 
mRNA, and no coupling conductance above background when injected with variant mRNA 
only17–19. Co-injection of GJB2 c.101T>C with wild-type connexin 30 (encoded by GJB6) 
or connexin 31 (encoded by GJB3) also showed reduced conductance19. Single channel 
conductance in c.101T>C transfected HeLa cells was reduced22, as supported by molecular 
dynamics simulations23. Furthermore, c.101T>C transfected HeLa cells did not transfer 
Lucifer yellow (a fluorescent dye) to neighbors across gap junctions as wild-type connexin 
26 transfected cells20,22,24 and the ability to transfer neurobiotin was also reduced.21 
However, c.101T>C transfected HeLa cells was able to load the dye in response to non-
physiological zero extracellular Ca2+ stimulus25, suggesting that p.Met34Thr variant 
connexin hemichannels may retain some residual function under unusual circumstances. The 
atomic structure of human connexin 26 gap junction channels revealed that the methyl group 
in p.Met34 interacts with p.Trp3 in the amino-terminal helix of an adjacent protomer to 
stabilize the hexameric channel26, and alteration of the residue was predicted to impact gap 
junction coupling27.
Similarly, Xenopus oocytes injected with mRNA encoding p.Val37Ile showed no 
conductance above background, and co-injection of p.Val37Ile variant connexin 26 with 
wild-type connexin 26, connexin 30, or connexin 31 showed reduced conductance19,28. 
Propidium iodide dye transfer was impaired in GJB2 c.109G>A transfected HEK293T 
cells29. Homozygous knock-in mouse model of c.109G>A in Gjb2 was reported to have 
progressive mild hearing loss, more pronounced at higher sound frequencies30. However, 
because the codon for p.Val37 in mouse (GTG) was different from that in human (GTT), 
c.109G>A in mouse would translate into p.Val37Met, it was not counted towards strong 
functional evidence. Nonetheless, this in vivo animal study was consistent with in vitro 
findings suggesting alteration of p.Val37 impacts GJB2 function.
These functional studies suggest p.Met34Thr and p.Val37Ile impact connexin 26 function; 
however, they may not truly reflect the biologic process in human cochlea.
Genotype-Phenotype Correlation
We obtained clinical information for 472 cases with biallelic GJB2 genotypes involving 
p.Met34Thr or p.Val37Ile (Table S2). P.Met34Thr was with a PTC in 86 cases, including 73 
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with c.35delG. P.Val37Ile was with a PTC in 92 cases, including 32 with c.235delC (Table 
4). We characterized hearing loss for different genotypes, although information was 
incomplete and non-uniform. Most cases had hearing loss before 18 years old. It was 
typically bilateral, mild to moderate, and affecting mid- to high- sound frequencies. 
Progression was reported in all genotype categories (Table 4). In some individuals, profound 
hearing loss could be due to age-dependent progression or other etiologies. For example, one 
had meningitis at 1.5 years old, one was 76 years old when tested, and one infant had 
asymmetric hearing loss with moderate loss in the left ear and severe-to-profound loss in the 
right ear (Table S2).
Ordered logistic regression models showed no statistically significant difference in severity 
among p.Met34Thr or p.Val37Ile homozygotes, [p.Met34Thr];[p.Val37Ile], and their 
corresponding compound heterozygotes with a PTC (p=0.93), but p.Met34Thr or p.Val37Ile 
homozygotes or compound heterozygotes with a PTC presented significantly milder hearing 
loss than a cohort of 63 c.35delG homozygotes (p<0.05), the majority of whom had 
profound hearing loss. [p.Met34Thr];[p.Val37Ile] compound heterozygotes also had milder 
hearing loss than c.35delG homozygotes, but the small sample size precluded statistical 
significance (Table 4).
One infant with [p.Val37Ile];[c.235delC] passed newborn hearing screening but audiology 
evaluation detected unilateral mild high-frequency hearing loss at five weeks, which 
progressed to bilateral mild high-frequency hearing loss at 20 weeks. One self-reported 
unaffected parent was found to be [p.Met34Thr];[c.167delT] via familial testing, and follow-
up audiology evaluation revealed mild high-frequency hearing loss at 47 years of age.
Taken together, phenotypic manifestation of GJB2 p.Met34Thr and p.Val37Ile related 
hearing loss varied from apparently normal to profound. However, these two variants were 
typically associated with bilateral mild to moderate sensorineural hearing loss, affecting 
high- to mid-sound frequencies. Progression has been reported. There was no significant 
difference in severity among p.Met34Thr or p.Val37Ile homozygotes and compound 
heterozygotes with another PTC (Table 4). The penetrance could not be calculated. 
However, among all individuals with biallelic GJB2 variants involving p.Met34Thr or 
p.Val37Ile, more compound heterozygotes than homozygotes were observed in our 
multicenter case cohort compared to the carrier screening population by Counsyl for both 
p.Met34Thr (OR 2.03, 95%CI 1.22–3.37, Z=2.7, p<0.0064) and p.Val37Ile (OR 1.90, 95% 
1.35–2.66, Z=3.7, p=0.0002), suggesting a higher penetrance for compound heterozygous 
genotypes than p.Met34Thr or p.Val37Ile homozygosity.
Summary Interpretation
In summary, p.Met34Thr and p.Val37Ile were classified as pathogenic based on PS4 
(homozygotes and compound heterozygotes are significantly enriched in cases over 
population controls), PP1_Strong (segregated with hearing loss in many affected family 
members), and PM3 (found in trans with many different pathogenic GJB2 variants in 
patients with hearing loss).
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DISCUSSION
Interpreting variants using case-control statistics
Maximum population allele frequencies for p.Met34Thr and p.Val37Ile are 2% in Finnish 
and 8% in East Asian in gnomAD, respectively, and in 3.5% (7/198) of Finnish and 17% 
(32/186) of Chinese Dai in Xishuangbanna in 1000 Genomes Project, respectively. The BA1 
(stand-alone for benign, population allele frequency >5%) criterion is not applicable here to 
p.Val37Ile, because of conflicting evidence suggesting pathogenicity. Based on professional 
judgement, the ClinGen HL-EP ruled that PS4 overrides BA1.
When applying PS4, we need to choose appropriate cases and controls. Because mild 
hearing loss may be underdiagnosed without a formal audiology evaluation, we opted to 
compare cases vs. population controls. Should results be significant in cases over population 
controls, they would be even more so in cases over unaffected controls.
We chose to use laboratory contributed data for cases instead of relying on published reports 
to avoid publication biases. Negative results are difficult to get published. Some patients 
may be included in multiple studies. Large cohort studies do not generally provide detailed 
case level data, and cases studies do not specify the total number of cases tested for the 
variant of interest.
In this study, we performed different types of case-control analyses. Although alleles were 
significantly enriched in cases with ORs of 1.3 (95%CI 1.2–1.5, Z=4.2, p<0.0001) for 
p.Met34Thr in Europeans (Table 2) and of 1.7 (95%CI 1.5–1.9, Z=8.1, p<0.0001) for 
p.Val37Ile in Asians (Table 3), the ORs did not exceed 5 to satisfy PS4 according to 
ACMG/AMP guidelines2, consistent with a previous meta-analysis31. However, ORs of 
homozygote frequencies met PS4. Hence, comparing individual frequencies is more 
appropriate than comparing allele frequencies in case-control analyses to interpret variants 
associated with an autosomal recessive condition, because unaffected heterozygous carriers 
contributed the majority of alleles.
We observed a larger effect when including compound heterozygotes, which implied a 
higher penetrance of other pathogenic variants in GJB2 than p.Met34Thr and p.Val37Ile. 
Our data indicate that it is preferable to include compound heterozygotes in analyses. 
Because individual data are unavailable from population databases such as gnomAD, 
population carrier screening data are invaluable.
Ethnicity information is crucial in case-control studies, because different ethnicity 
compositions could confound results. In this study, we found significances were inflated 
when ethnicity information was disregarded. Proportions of p.Met34Thr and p.Val37Ile 
homozygotes varied significantly among laboratories due to different population 
compositions tested. Combining data from different laboratories while ignoring ethnicity 
information would bias towards the ethnic composition of the laboratory that contributed the 
most data. Stratifying patients by ethnicity significantly reduces the bias but decreases the 
sample size. Combining data from laboratories around the world allowed us to perform 
unbiased analysis with sufficient statistical power. Unfortunately, ethnicity information is not 
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always submitted to testing laboratories, and some laboratories do not collect such 
information. Furthermore, ethnicity in gnomAD was inferred based on principal component 
analysis, which may differ from self-reported ethnicity; gnomAD tends to over-estimate 
major populations as people with a self-reported mixed ethnic background would likely be 
counted towards one of the major populations. Therefore, we recommend laboratories 
collect ethnic information on the test requisition form and request patients and physicians to 
provide such information when ordering genetic tests.
Genotype-phenotype correlation
Variable expressivity of p.Met34Thr and p.Val37Ile has been reported16,32. The hearing loss 
may be unilateral or bilateral, from mild to profound, affecting different frequency ranges, 
even in individuals with the same genotype. P.Val37Ile has also been associated with 
pathopoieia33 and sudden hearing loss34. There have been over 100 publications reporting 
individuals with these variants. However, case-level genotype and phenotype data were 
limited. This multicenter study found over 96% of biallelic p.Met34Thr or p.Val37Ile cases 
with bilateral hearing loss including a small percentage with asymmetric presentations, 84% 
with mild to moderate hearing loss, and a majority with high-frequency loss, consistent with 
previous reports35–38. Individuals with profound hearing loss may have an alternate etiology 
such as infection or old age. Unilateral or asymmetrical hearing loss may progress to 
bilateral uniform.
The majority of diagnosed cases in our multicenter cohort had a pediatric onset of hearing 
loss. The findings could be due to ascertainment bias, because most individuals undergoing 
genetic diagnosis are younger than 18 years old. Adults with mild hearing loss may not seek 
audiology evaluation or genetic testing. Progression of hearing loss was only reported in a 
small percentage of cases, because the progression was slow15 and long-term follow-up 
information was unavailable.
We confirmed incomplete penetrance of these two variants. Three Asian p.Val37Ile 
homozygotes and two Ashkenazi Jewish p.Met34Thr compound heterozygotes were 
confirmed unaffected by audiology evaluation with the oldest known age at testing of 30 
years (Table 5). We also identified 411 individuals with biallelic p.Met34Thr (189) or 
p.Val37Ile (238) via carrier testing. However, the penetrance could not be quantified based 
on our data, because they might be truly unaffected or underdiagnosed. It has been estimated 
that the penetrance of p.Val37Ile homozygotes was 17% in children in China16, but the 
number could vary by age, ethnicity, and the allele in trans in compound heterozygotes. Our 
data suggest that the penetrance is higher in p.Met34Thr or p.Val37Ile compound 
heterozygotes than in corresponding homozygotes.
The mechanism for incomplete penetrance and variable expressivity remains elusive. 
Environmental and genetic modifiers may play a role. It is unclear how many different 
haplotypes were involved and whether the phenotype is haplotype-dependent. The haplotype 
with c.−684_−675del in 5’UTR of NM_004004.5 (rs139514105, referred to as c.−493del10) 
in cis with p.Met34Thr was confirmed in an affected sibpair from the UK8 and seven 
affected German individuals39, but its frequencies in all affected and unaffected biallelic 
p.Met34Thr populations are unknown. This haplotype did not abolish GJB2 expression in 
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cultured keratinocytes, which argues against a regulatory role of the noncoding cis variant8. 
Identification of the modifiers will not only help interpret the genetic findings but also point 
to effective therapeutic strategies for GJB2-related hearing loss, the most common form of 
hereditary hearing loss. Given the high allele frequency of these two variants in the 
population, further studies to identify modifiers through population genetic screening and 
phenotypic evaluation of biallelic individuals are warranted and feasible.
Barriers to accurate variant interpretation
Our experience in analyzing p.Met34Thr and p.Val37Ile in GJB2 revealed barriers to 
accurate variant interpretation. First, no phenotypic information was available in large 
population studies or population screening. Although we were able to achieve statistical 
significance with a large sample size, should hearing status in the general population be 
known, a much smaller sample size would be sufficient to provide the same level of 
statistical power. Second, incomplete ethnicity, family history and clinical information from 
laboratories and publications diminished the usefulness of many cases. We would urge 
ordering physicians and testing laboratories to collect and share such information and editors 
and peer-reviewers to encourage publication of detailed case-level information. Third, case 
information was biased towards published case reports usually by clinicians and genetic 
service centers. Although they provided detailed clinical information, matched control 
information was mostly unavailable. A systematic patient registry to document harmonized 
clinical and genetic information will overcome this. Finally, given the slow progressiveness 
and variable expressivity, we still could not accurately determine the penetrance of these 
variants in manifesting hearing loss and pinpoint the factors that influence the penetrance. 
Although age seems to be a factor, it could not explain everything. Long-term follow-up of 
individuals with these variants in prospective studies will illuminate in this area.
CONCLUSION
We conclude that the ACMG/AMP variant interpretation framework can be applied to 
variants with incomplete penetrance. Large and diverse sample sizes are required to 
overcome limitations and draw valid conclusions. The ClinGen HL-EP established a 
collaborative model of operation to collect case-level data, which allowed unbiased analysis 
of p.Met34Thr and p.Val37Ile, two controversial variants in GJB2. Based on compelling 
statistical and supporting functional evidence, we conclude that the two GJB2 variants meet 
criteria to be classified as pathogenic for autosomal recessive sensorineural hearing loss, 
typically bilateral mild to moderate and slowly progressive over time15. When these variants 
are identified in homozygosity or compound heterozygosity in GJB2 in cases with profound 
hearing loss, an alternate etiology should be investigated.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 2.
Summary statistics for p.Met34Thr
All1 Cases2 Population3 Counsyl OR 95% CI Z P value
Total number of individuals tested for GJB2 17635 802339 654426
Total number of alleles tested for GJB2 35270 1604678 1308852
Total number of individuals with p.Met34Thr 391 10835 8336
Total number of p.Met34Thr heterozygotes 362 10754 8282
Total number of p.Met34Thr homozygotes 29 81 54 16 11–25 13 <0.0001
Total number of p.Met34Thr compound heterozygotes4 147 NA5 135
Total number of p.Met34Thr alleles 420 10916 8390
Overall p.Met34Thr allele frequency 0.0119 0.0068 0.0064
Number of European individuals tested for GJB2 7962 382842 304433
Number of European alleles tested for GJB2 15924 765684 608866
Number of European individuals with p.Met34Thr 207 7915 5769
Number of European p.Met34Thr heterozygotes 193 7846 5725
Number of European p.Met34Thr homozygotes 14 69 44 9.8 5.5–17 7.8 <0.0001
Number of European p.Met34Thr compound heterozygotes4 
with another GJB2 pathogenic allele
84 N/A5 886 296 22–376 256 <0.00016
Number of European p.Met34Thr alleles 221 7984 5813 1.3 1.2–1.5 4.2 <0.0001
p.Met34Thr allele frequency in Europeans 0.0139 0.0104 0.0095
1.Only probands (unrelated individuals) were counted. However, we could not rule out the possibility of related cases from different sites because 
cases were de-identified before being shared. Nevertheless, the likelihood of such occurrence would be low and would not significantly impact the 
conclusion.
2.
The total number of cases included in statistical analyses did not include BCH, DY, and GDWC where the total number of individuals tested at 
these sites were not available.
3.
The total population data were from Counsyl, CUHK, TAU, UNC, and gnomAD.
4.Compound heterozygosity was presumed in individuals with a second pathogenic or likely pathogenic variant in GJB2 that had never been 
reported to have occurred in cis.
5.NA: Not available, because individual allele state information is not available from gnomAD.
6.Analyses involving compound heterozygotes were performed using Counsyl data as the population control (see Methods).
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Table 3.
Summary statistics for p.Val37Ile
All1 Cases2 Population3 Counsyl OR 95% CI Z P value
Total number of individuals tested for GJB2 17635 802339 654426
Total number of alleles tested for GJB2 35270 1604678 1308852
Total number of individuals with p.Val37Ile 464 10233 7609
Total number of p.Val37Ile heterozygotes 313 9887 7370
Total number of p.Val37Ile homozygotes 151 346 239 20 17–24 31 <0.0001
Total number of p.Val37Ile compound heterozygotes4 115 N/A5 96
Total number of p.Val37Ile alleles 615 10488 7848
Overall p.Val37Ile allele frequency 0.0174 0.0065 0.0060
Number of Asian individuals tested for GJB2 2066 75857 60355
Number of Asian alleles tested for GJB2 4132 151714 120710
Number of Asian individuals with p.Val37Ile 197 6173 4023
Number of Asian p.Val37Ile heterozygotes 113 5898 3852
Number of Asian p.Val37Ile homozygotes 84 275 171 12 9.1–15 19 <0.0001
Number of Asian p.Val37Ile compound heterozygotes4 with 
another GJB2 pathogenic allele
49 N/A5 466 196 15–246 266 <0.00016
Number of Asian p.Val37Ile alleles 281 6360 4194 1.7 1.5–1.9 8.1 <0.0001
p.Val37Ile allele frequency in Asians 0.0680 0.0419 0.0347
1.Only probands (unrelated individuals) were counted. However, we could not rule out the possibility of related cases from different sites because 
cases were de-identified before being shared. Nevertheless, the likelihood of such occurrence would be low and would not significantly impact the 
conclusion.
2.
The total number of cases included in statistical analyses did not include BCH, DY, and GDWC where the total number of individuals tested at 
these sites were not available.
3.
The total population data were from Counsyl, CUHK, TAU, UNC, and gnomAD.
4.Compound heterozygosity was presumed in individuals with a second pathogenic or likely pathogenic variant in GJB2 that had never been 
reported to have occurred in cis.
5.NA: Not available, because individual allele state information is not available from gnomAD.
6.Analyses involving compound heterozygotes were performed using Counsyl data as the population control (see Methods).
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Table 5.
Unaffected p.Met34Thr or p.Val37Ile homozygotes or compound heterozygotes confirmed by audiology 
evaluation.
Site ID Var 1 DNA Var 1 AA Var 2 DNA Var 2 AA Age tested Family history Ethnicity
LMM 56s c.109G>A p.Val37Ile c.109G>A p.Val37Ile 7 years old sibling Asian
NTMC 101 c.109G>A p.Val37Ile c.109G>A p.Val37Ile 28 years old no Asian
NTMC 102 c.109G>A p.Val37Ile c.109G>A p.Val37Ile 30 years old no Asian
TAU 13 c.101T>C p.Met34Thr c.269T>C p.Leu90Pro Adult unknown Ashkenazi/Iraqi Jewish
TAU 14 c.101T>C p.Met34Thr c.167delT p.Leu56Argfs unknown unknown Ashkenazi Jewish
Individuals without phenotypic information or audiology evaluation are not listed.
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